DIAGNOS Sets AGM and Extends Warrants
Analysis based on 8 articles · First reported Sep 14, 2026 · Last updated Sep 14, 2026
The announcement is a routine corporate governance and capital structure update for a small TSX Venture-listed company, with negligible impact on broader markets. The warrant extensions modestly reduce near-term dilution and expiry pressure on Diagnos shares, but the effect is limited to the company itself.
Diagnosis announced on September 14, 2026 that its 2026 annual general meeting of shareholders will be held on September 30, 2026 at 10:00 a.m. at the Alt Quartier DIX30 Hotel in Brossard, Quebec. The meeting agenda includes electing directors, reappointing Raymond Chabot Grant Thornton LLP as independent auditor, and authorizing the directors to set the auditor remuneration. Shareholders of record as of August 26, 2026 are entitled to vote in person or by proxy, with the 2026 Management Information Circular mailed on September 3, 2026 and available on SEDAR+. The company also extended the expiry dates of two series of stock warrants while keeping the exercise price unchanged at $0.40: 4,603,668 warrants issued October 25, 2024 now expire September 25, 2026 instead of April 25, 2026, and 6,715,369 warrants issued February 5, 2025 now expire June 5, 2027 instead of August 5, 2026. Diagnos is a Canadian public corporation focused on AI-based early detection of eye-related health pathologies.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard